Full-Time

Executive Director Marketing – Global Skin Lead

Oncology Business Unit

Posted on 8/23/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceutical therapies for serious diseases

Compensation Overview

$251.2k - $418.6k/yr

Tarrytown, NY, USA

Hybrid

On-site in Sleepy Hollow, NY 4 days per week and 1 day from home.

Category
Growth & Marketing (2)
,
Required Skills
Marketing
Data Analysis
Requirements
  • A bachelor’s degree is required.
  • 15+ years of progressive pharmaceutical sponsor side industry or relevant professional experience.
  • Deep experience in global commercial, marketing, and brand positioning and strategy development for oncology projects in US
  • Experience in marketing outside of US markets with an appreciation for high-level access and commercial challenges in those markets/geographic regions
  • Exemplary marketing technical skills, ranging from strategy to tactical execution, extensive experience in and understanding of brand management
  • Proven track record of market analysis and identifying growth opportunities on a global scale
  • Understanding of global to local market trade-offs during global commercialization planning for Oncology assets
  • Must be willing to travel 25-30% (including weekend and international travel as needed)
  • People mgmt experience
  • Experience leading cross-functional teams within a pharmaceutical or healthcare organization in the US and outside of the US, specifically for oncology assets
  • Experience adapting strategies based on market access, regulatory, development, and other cross-functional considerations
  • Experience creating and driving initiatives to support global launch planning and marketing, and life cycle management strategy and planning
  • Experience in leading and developing long range brand plans, budgets and forecasts within commercial teams in the pharma/biotech industry
  • Strong analytical skills for ease of tracking and communicating metrics
  • Ability to communicate HCP/KOL engagement levels and overall project results to management and cross-functional partners
  • Strong project and process skills with attention to detail
  • Ability to communicate and act promptly; demonstrated initiative, creativity, and ability to stay agile and work effectively in complex, rapidly changing environments.
  • Must be proactive and able to prioritize, comfortable leading in ambiguity
  • Good interpersonal and presentation skills both internally & externally, as well as other professional/productive behaviors conducive to a productive and positive team environment
  • Proficient understanding of how countries’ economic systems influence treatment availability, especially knowledgeable of oncology provider treatment environment in US and economics across academic and community hospitals and clinics, Buy & Bill, SPs, GPOs, IDNs, PHS hospitals, hospital and system pharmacy, and payers.
  • Understanding of oncology therapeutic area, drug development process, & regulatory environment
  • Extensive people management experience
Responsibilities
  • Leading, and inspiring large marketing tumor focused marketing team with US and International HQ marketing team members as well as US field based team members.
  • Establishing the global tumor strategy to drive differentiation and portfolio value across geographies, balancing US and International market input into global strategy build US, International HQ marketing team members and US field based team members
  • Planning business effectively for global and local market execution, being agile and able to balance/prioritize overall tactical initiatives to build and execute strategy
  • Driving global brand planning, able to use tumor strategic thinking to develop meaningful brand and asset strategies to increase the value of the assets in these tumor areas.
  • Working in close collaboration with Clinical, Medical Affairs and Field Medical to ensure strategic alignment with Medical Education strategic plans
  • Providing strategic input into Skin Marketing Team collaboration with Insights and Data Analytics teams to conduct global market analyses and translate them into clear strategic choices and prioritization globally, ensuring team has insights and data needed to do so
  • Representing the tumor area in decision-making forums (e.g., Commercial/Clinical cross-functional committees) to influence prioritization, resource allocation, and long-range planning based on scientific & commercial potential
  • Working closely/collaboratively with other disease area leads to ensure overall alignment and synergy for the brand
  • Manages team of direct reports and their respective teams, ensuring alignment with Global strategy and vision, and providing input/direction into critical activities/initiatives as well as prioritization
  • Develops professional relationships and contacts with global physician experts and attends key congresses
  • Creates processes and drives initiatives related to commercial launch and marketing efforts, proactively addressing hurdles in oncology asset commercialization where applicable
  • Maintains line of sight to global P&L for skin cancer products across markets and accountable for US P&L
  • Ensuring the development, implementation, and administration of marketing processes, programs, and internal reports are consistent with corporate guidance and all regulatory, legal, ethical guidelines
  • Supporting team efforts to develop promotional content, including ensuring Medical/Legal/Regulatory Review committee effectiveness
  • Managing and developing team members, ensuring their continued development and growth.
  • Ensuring that team develops and tracks KPIs to monitor success of promotional activities and refines strategy/tactics based on KPI outcomes
  • Providing consistent reporting of status, future planning, and issues/challenges to VP of Global Oncology Marketing, ensuring alignment with VP and senior leadership on strategic planning
  • Ensuring alignment with other disease area leads
  • Creating, managing and tracking US and Global budget within Skin to ensure team is operating within the approved budget and phasing and proactively identifying efficiencies
  • Ensuring alignment with Lung or other Disease leads
Desired Qualifications
  • Preferred- Prior pharmaceutical sales experience
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent global sales surged 33% to $4.9B in Q1 2026, treating 1.4M patients across nine indications.
  • Libtayo net sales grew 54% to $438M in Q1 2026 from CSCC and lung cancer uptake.
  • $27B US R&D and manufacturing commitment secures three-year tariff relief via April 2026 Trump deal.

What critics are saying

  • Biosimilar aflibercept from Viatris erodes legacy EYLEA sales, dropping combined franchise 10% to $941M in Q1 2026.
  • Sanofi renegotiates Dupixent profit-sharing as sales hit $4.9B, cutting Regeneron's 25-50% economics by 2028.
  • Trump most-favored-nation deal mandates Medicaid price cuts on EYLEA and Dupixent, slashing margins 30-50% by mid-2027.

What makes Regeneron Pharmaceuticals unique

  • Proprietary VelociSuite technologies enable rapid homegrown drug discovery across modalities.
  • Developed EYLEA HD with unique 5-month dosing for wet AMD approved by FDA in Q1 2026.
  • Pioneered Otarmeni, first in vivo gene therapy for OTOF-related hearing loss, FDA-approved April 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Endpoints News
Apr 13th, 2026
Regeneron wades into radiopharma through $40M upfront deal with telix.

Regeneron wades into radiopharma through $40M upfront deal with telix. News reporter. Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumor therapies as... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. Think Endpoints Company is worth reading - tell google. Confirm Endpoints as a trusted biopharma news source ENDPOINTS CAREERS TCG stealth clinic-ready newco.

AllSci
Apr 13th, 2026
Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal.

Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal. April 13, 2026 Australia-based Telix Pharmaceuticals Ltd (ASX: TLX, Nasdaq: TLX) and US firm Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced a strategic collaboration to jointly develop and commercialize next-generation antibody-based radiopharmaceutical therapies across multiple solid tumor indications. The agreement pairs Telix's radiopharmaceutical development platform and global manufacturing infrastructure with Regeneron's antibody discovery technologies, including its VelocImmune and VelociSuite platforms, to generate a pipeline of radiolabeled biologics. Specific tumor targets have not been disclosed. Deal specifics. Under the deal terms, Telix will receive an upfront payment of USD 40 million from Regeneron for access to its radiopharmaceutical manufacturing platform across four initial therapeutic programs. Should Telix elect to opt out of co-funding on any individual program, it becomes eligible to receive up to USD 535 million in development and commercial milestone payments per program, plus low double-digit royalties on net sales, with an aggregate milestone ceiling of USD 2.1 billion across all programs. Where Telix remains in the co-funding model, the two companies will share equally in global development costs and commercialization profits on a 50/50 basis, with Telix retaining the option to co-promote certain products. The collaboration covers four initial therapeutic programs, with Regeneron holding the option to expand to four additional programs subject to further upfront payments. The parties will also jointly develop radio-diagnostic assets to support patient selection and treatment response monitoring, with Telix leading commercialization of those diagnostics and Regeneron receiving a defined percentage of profits. The exact percentage was not disclosed. The structure gives Telix a per-program election right at a defined decision point: co-fund and share in global profits equally, or opt out and revert to a milestone-plus-royalty economics model. This optionality allows Telix to allocate capital selectively depending on program progression and resource constraints, while preserving upside participation across the portfolio. The agreement is global in scope, with no geographic carve-outs or territorial allocations disclosed. No equity investment by either party in the other was announced in connection with the transaction. The drug programs will combine Regeneron's antibody targeting components, drawn from its portfolio of antibodies generated through VelocImmune mice, with Telix's radiolabeling and manufacturing capabilities. The modality class is antibody-based radiopharmaceutical therapy, in which a tumor-antigen-binding antibody serves as the targeting vehicle for a therapeutic radionuclide payload. The collaboration also encompasses potential bispecific antibody formats, given Regeneron's established expertise in that area. Regeneron noted in its public commentary that it intends to explore these agents as monotherapy and in rational combination with its immunotherapy platform, citing lung cancer as one area of interest where its PD-1 inhibitor is already in use. The specific antigens, antibody names, and radionuclide payloads for the collaboration programs have not been publicly identified. The theranostic component of the agreement, pairing matched diagnostic and therapeutic agents using the same antibody targeting vector, supports patient stratification and dosimetry assessment ahead of and during treatment. Telix will lead commercialization of the diagnostic assets developed under the collaboration. Strategic implications. Regeneron's entry into radiopharmaceutical oncology drug development marks a modality expansion for a company whose oncology portfolio has been anchored in antibody-based immunotherapy. The company indicated it views targeted radiopharmaceuticals as a frontier in oncology and has framed the collaboration as an opportunity to apply its antibody discovery engine to a delivery modality it has not previously pursued commercially. For Telix, the arrangement provides validation of its radiopharmaceutical manufacturing infrastructure as a platform asset capable of attracting large-scale co-development partnerships. Telix's existing commercial radiopharmaceutical portfolio includes Illuccix kit for the preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC injection (also known as 68Ga-PSMA-11 injection), approved by the US FDA as a prostate cancer imaging agent. In addition, the firm announced on April 9, 2026, that the US FDA has accepted an NDA filing for TLX101-Px (Pixclara, Floretyrosine F 18 or 18F-FET), an investigational PET agent for the imaging of glioma (brain cancer). Your email address will not be published. Required fields are marked *

GlobalData
Apr 13th, 2026
Telix and Regeneron to co-develop radiopharmaceutical therapies.

Telix and Regeneron to co-develop radiopharmaceutical therapies. The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses. Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical platforms, global manufacturing and supply chain infrastructure with Regeneron's biologics knowledge, particularly in bispecific antibody discovery. Regeneron will initially provide Telix with an upfront cash payment of $40m for access to the latter's radiopharmaceutical manufacturing platform for four therapeutic initiatives. There is an option for Regeneron to expand to another four programmes, which would involve further upfront payments. Both companies will equally share the costs and potential profits worldwide, with Telix optionally co-promoting certain products. If Telix chooses to step back from funding a specific programme, it could gain up to $535m in developmental and commercial milestones, in addition to low double-digit royalties on subsequent net sales. Regeneron oncology and antibody technology research senior vice-president John Lin said: "At Regeneron, Pharmaceutical Technology follow the science to determine the best therapeutic approach for each disease, continuously expanding its toolbox of treatment modalities - from monoclonal and bispecific antibodies to cell therapies and beyond. "Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need." The collaboration will include several solid tumour targets from Regeneron's antibody portfolio, benefiting from its VelocImmune mice technology. It reflects a joint focus on precision oncology, seeking to enhance patient selection and assess treatment responses through new radio-diagnostics. The companies also plan to develop diagnostic assets, where Telix will spearhead the commercialisation efforts, and Regeneron will receive a predetermined share of the profits. In December 2025, Regeneron teamed up with Tessera Therapeutics to develop and commercialise Tessera's rare disease in vivo gene writing programme, TSRA-196. Give your business an edge with its leading industry insights.

Yahoo Finance
Apr 13th, 2026
Dupixent approved in EU as first targeted medicine for chronic spontaneous urticaria in children aged 2-11

Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years. The approval applies to patients with inadequate response to histamine-1 antihistamines who are naïve to anti-immunoglobulin E therapy. This expands Dupixent's existing EU approval for CSU, which previously covered adults and adolescents aged 12 and older. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. The approval is based on data from the LIBERTY-CUPID clinical trial programme, including efficacy data extrapolated from two Phase 3 adult trials and pharmacokinetic, safety and efficacy data from the CUPIDKids Phase 3 trial in children aged 2 to 11.

The Associated Press
Apr 13th, 2026
EU approves Sanofi and Regeneron's Dupixent as first targeted medicine for young children with chronic urticaria

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years with inadequate response to antihistamines. Developed by Sanofi and Regeneron, this marks the first targeted medicine for young children with the condition in the EU. The approval, based on the LIBERTY-CUPID clinical study programme, expands Dupixent's CSU indication to children as young as two years. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. Clinical studies showed Dupixent significantly reduced urticaria activity, including itch and hives, compared with placebo at Week 24. Safety results were consistent with Dupixent's known profile in dermatological indications. A supplemental biologics licence application is under review in the US for the same patient population.

INACTIVE